This year at Oracle HS Connect, ObvioHealth and Oracle will be challenging a deep-rooted industry narrative that opposes site-based approaches with decentralized ones. Hybrid studies are all about leveraging the best of both worlds. So, let’s talk about how to get the most out of them!
During the event, Scott Dixon will be sitting down with Oracle Health Science’s Solution Director, Satoshi Soma, to discuss how DCT capabilities—including remote ePRO—can improve clinical trial conduct by giving investigators and study teams line of sight into patients between visits.
Don’t miss your chance to learn more about how the ObvioHealth-Oracle partnership is generating stronger evidence for clinical trials.
Fill out the form below to schedule a meeting with Scott Dixon.
Scott, a versatile leader, has spent over 25 years bringing integrated commercial and operational planning expertise to life science, pharmaceutical, and healthcare software companies—including Flywheel, Suvoda, Clario, and Oracle. Scott’s results-driven mindset is leading ObvioHealth’s commercial team in the successful global rollout of its next-generation DCT platform and app.
ObvioHealth is an end-to-end virtual research organization (VRO), combining the clinical excellence of the best CROs with pioneering technology. Powered by these three key differentiating capabilities, we optimize hybrid clinical trials at every stage and touchpoint— streamlining the process for patients, sites, and sponsors alike.